Table 5.
Borderline Personality Disorder.
| Borderline Personality Disorder | |||||
|---|---|---|---|---|---|
| Study | Study Design | Drugs and Dose | Cohort | Treatment duration | Results |
| Bellino et al., 2014 [132] |
Randomized, controlled trial | 1.2 g/day EPA + 0.6 g/day DHA + 800–1300 mg/day valproic acid vs. 800–1300 mg/day valproic acid (plasma range: 50–100 μg/mL) |
43 BPD patients (18 to 50 years) | 12 weeks | ↓ severity of BPDSI ↓ impulsive behavioral dyscontrol ↓ anger ↓ self-mutilating conduct |
| Bozzatello et al., 2018 [133] |
Follow-up study to Bellino et al., 2014 | 1.2 g/day EPA + 0.6 g/day DHA + 800–1300 mg/day valproic acid vs. 800–1300 mg/day valproic acid (plasma range: 50–100 μg/mL) |
34 patients with BPD (18 to 50 years) |
24 weeks | ↓ outbursts of anger |
| Raine et al., 2021 [134] |
Randomized, double-blind, placebo-controlled Trial | 300 mg DHA + 300 mg EPA + 180 mg alpha-linolenic acid + 60 mg DPA | 324 children (11.89 years (SD 2.59)) | 52 weeks | ↓ aggression, ↓ antisocial behavior |
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; DPA = n-3 docosapentaenoic acid; BPDSI = borderline personality disorder severity index; ↓ = improvement of.